Comment: Looking ahead to Genesis 2022 

The annual Genesis conference will take place on 7 December 2022 in London, and 5,6 and 8 December online, bringing key opinion leaders, investors and innovators from across the life sciences sector under one roof to exchange insights, debate trends and generate deals. DDW’s Megan Thomas will be in attendance and looks ahead at the programme which centres around the theme of “Maximising Returns from Life Science Innovation”. 

Genesis has been taking place for more than 20 years now and the preliminary keynote programme covers a range of industry bases, including: global health challenges, sustainability, economics, as well as inclusion and equality in the industry. After a welcome note from One Nucleus’ Jon Green, attendees can expect to hear from Mike Ward, Global Head of Life Sciences & Healthcare Thought Leadership at Clarivate. He will be speaking on the “Winners & Losers 2022”, following the release of Clarivate’s annual Highly Cited Researchers list, which identifies 6,938 individuals at universities, research institutes and commercial organisations across 69 countries/regions who have demonstrated a disproportionate level of significant and broad influence in their field(s) research.  

Thereafter, a panel discussion, moderated by Amy Brown, Deputy Editor of Evaluate Vantage, will take a look at the latest trends in life science investment and partnering deals. Panelists Julie Simmonds (Panmure Gordon), James Fry (Mills & Reeve), Will Walker-Arnott (Charles Stanley Wealth Management), Kate Rowley (Global Bio Fund), and Jérôme Van Biervliet (VIB) will attempt to answer the question of what previous financing cycles have taught us.  

Later in the programme, Genesis 2022 attendees will have the opportunity to learn about what the life science landscape will look like in 2023. Moderated by tranScrip’s Paul Branthwaite, panellists Laura Lane (Eli Lilly), David Roblin (Relation Therapeutics) and Miguel Forte (Bone Therapeutics) will uncover the stakeholders shaping and disrupting the sector will be in 2023 and beyond, what technologies in R&D, drug discovery or related field will provide the best solutions for patients, as well as when we will begin to see results.   

There will also be a debate between Catherine Stace (Domainex), Max Bryan (Bidwells), Michael Chen (Nuclera), John McCafferty (Maxion Therapeutics), and Nick Foster (Metrion Biosciences), called “The Golden Triangle is a better exosystem to grow a life science company than Massachusetts”, after which the audience will vote in favour or in opposition to the title statement. 

The afternoon promises three panel discussions: ‘Is Technology Diversifying Biomedical R&D Outputs?’, ‘Value Creation and Sharing in a Converging World’, and ‘The Anatomy of a Life Science Leader’. In the first, moderator Lisa Melton from Nature Biotechnology, alongside panellists Rowan Gardner (PrecisionLife), Andy Richards (Ieso Digital Health), Niklas Blomberg (ELIXIR Europe), and Victor Neduva (MSD), discuss whether the ability to generate, collect and analyse data from diverse sources is leading to greater diversity in areas such as target selection and drug design, patient stratification in clinical trials, scale of collaboration, and skills. In the second, moderator Victoria English from MedNous, alongside panellists Hannah Sore (PharmEnable), Chris Wayman (EY), Claire Smith (Bristows), Nuno Alves (Astellas Pharma), and Peter Peumans (imec) discuss how we collaborate to protect, capture, and share created value equitably when considering the rate at which R&D is evolving with a dependency on Big Data/AI, external partnerships and global markets. In the third panel of the afternoon, moderator Mike Ward from Clarivate guides panellists Suzanne Holden (Thermo Fisher), Anji Miller (LifeArc), Barry Winkless (Cpl Future of Work Institute), Jacqui Watson (Inivata), and Lisa Page (Penningtons Manches Cooper) through a conversation about what successful leadership traits are needed to build a life science company that leads with innovation. 

Attendees will also have an opportunity to hear Claire Thompson, CEO of Agility Life Sciences, and Miranda Knaggs, Corporate Development Director of We Are Pioneer Group, on reshaping the UK Life Sciences sector.   

Registration is still possible at

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free